Le Lézard
Classified in: Health
Subject: SVY

Tuberculosis Testing Market, Nucleic Acid Testing, Xpert Test, Serological Tests, and Smear Microscopy - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2017-2025


NEW YORK, Nov. 21, 2017 /PRNewswire/ -- Global Tuberculosis Testing Market: Overview

Tuberculosis testing can be defined as the most commonly used diagnostic tools for the tuberculosis. Tuberculosis is defined as an infectious disease which characterized by development of tubercles (nodules) in the body tissues, especially in the lungs. The market is anticipated to grow at a significant rate owing to various factors such as high return on investments, first-mover advantage to the tuberculosis test kits manufacturers, growing focus on awareness programs by the governmental and non-governmental organizations, and tax credits and fee waivers offered by the government, among others.

Read the full report: https://www.reportlinker.com/p05210076

The research is a combination of primary and secondary research, conducted for understanding and arriving at trends, used to forecast the expected revenue of tests employed in the diagnosis of tuberculosis in the near future. Primary research formed the bulk of our research efforts with information collected from in-depth interviews and discussions with a number of key industry experts and opinion leaders. Secondary research involved study of company websites, annual reports, press releases, investor presentations, analyst presentation and various international and national databases. The report provides estimated market size in terms of US$ Mn for test type, end-user, and geography for the period 2015 to 2025, considering the macro and micro environmental factors. The revenue generated from each test type, and end-user was calculated by considering the prevalence of tuberculosis, testing approvals, regulatory procedures, and the awareness of tuberculosis across all the geographies.

Global Tuberculosis Testing Market: Segmentation

The market report comprises an elaborated executive summary, which includes market snapshot that provides information about various segments of the market. It also provides information and data analysis of the market with respect to market segments based on test type, end-user, and geography. The market overview section of the report analyzes market dynamics such as drivers, restraints and opportunities that influences the tuberculosis testing market in the current and future scenario. The report also provides Porter's five forces analysis, the acquisitions timeline of tuberculosis testing companies, SWOT analysis of the market, regulatory scenario, comparative analysis of tuberculosis testing policies, tuberculosis prevalence globally, pricing scenario of the tuberculosis testing, and major used tuberculosis tests.

Global Tuberculosis Testing Market: Competitive Analysis

Market share analysis among the market players is analyzed to signify the contribution of these players in the market in terms of percentage share. All these factors will help the market players to decide about the business strategies and plans to strengthen their positions in the global market. Based on geography, the market has been analyzed for major regions: North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The study also covers detailed country analysis contributing majorly in the tuberculosis testing market.

The report also profiles the major players in the market and provides various attributes such as company overview, financial overview, product portfolio, business strategies, and recent developments. Companies profiled in the tuberculosis testing market report are Becton, F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., Hain Lifescience GmbH, Hologic Inc., Abbott Laboratories, Alere Inc., Epistem plc, Cepheid, bioMérieux SA, Akonni Biosystems Inc., LIONEX Diagnostics & Therapeutics GmbH., Danaher Corporation, Creative Diagnostics, QIAGEN, and Oxford Immunotec Ltd. among others.

The Tuberculosis Testing Market has been segmented as follows:

Global Tuberculosis Testing Market, by Test Type
Chest X-Ray
Culture Based Tests
IGRA (Interferon-Gamma Release Assays)
Mantoux Test (TST)
Nucleic Acid Testing (NAT), Xpert test
Serological Tests
Smear Microscopy
Other Tests (ADA, etc.)

Global Tuberculosis Testing Market, by End-User, Revenue
Academics and Research
Hospitals Laboratories
Physician's Office Laboratories
Reference Laboratories
Others (Home Health Agencies, etc.)

Global Tuberculosis Testing Market Revenue, by Geography
North America
U.S.
Canada
Europe
U.K.
Germany
Spain
France
Italy
Rest of Europe
Asia Pacific
China
India
Japan
Australia & New Zealand
Rest of Asia Pacific
Latin America
Brazil
Mexico
Rest of LATAM
Middle East and Africa
GCC Countries
South Africa
Rest of MEA

Read the full report: https://www.reportlinker.com/p05210076

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________
Contact Clare: [email protected]
US: (339)-368-6001
Intl: +1 339-368-6001

 

SOURCE Reportlinker


These press releases may also interest you

at 16:15
Exelixis, Inc. today announced that members of the company's management team will participate in fireside chats at the following investor conferences in May: BofA Securities 2024 Health Care Conference: Exelixis is scheduled to present at 2:20...

at 16:10
Savara Inc. , a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that its management team will participate in a fireside chat at the Citizens JMP Life Science Conference on May 14, 2024 at 6:00am...

at 16:10
Janux Therapeutics, Inc. (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated...

at 16:10
AbCellera today announced financial results for the first quarter of 2024. All financial information in this press release is reported in U.S. dollars, unless otherwise indicated. "We continue to execute on advancing our internal pipeline,...

at 16:10
Veracyte, Inc. today announced financial results for the first quarter ended March 31, 2024. "We had a strong start to 2024, driven by robust growth from our market-leading Decipher Prostate and Afirma tests. We executed upon our strategies to...

at 16:10
Pulse Biosciences, Inc. , a company leveraging its novel and proprietary CellFX® Nanosecond Pulsed Field Ablationtm (nsPFAtm) technology, today announced business updates and financial results for the first quarter ended March 31, 2024. Recent...



News published on and distributed by: